Market Research Industry Reports

Aspergillosis - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Aspergillosis - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Pipeline Review, H1 2018, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 6, 17 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 3 molecules, respectively.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 5
Aspergillosis - Overview 6
Aspergillosis - Therapeutics Development 7
Aspergillosis - Therapeutics Assessment 14
Aspergillosis - Companies Involved in Therapeutics Development 23
Aspergillosis - Drug Profiles 31
Aspergillosis - Dormant Projects 107
Aspergillosis - Discontinued Products 109
Aspergillosis - Product Development Milestones 110
Appendix 123

List Of Tables

List of Tables
Number of Products under Development for Aspergillosis, H1 2018 11
Number of Products under Development by Companies, H1 2018 13
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 14
Number of Products under Development by Universities/Institutes, H1 2018 15
Products under Development by Companies, H1 2018 16
Products under Development by Universities/Institutes, H1 2018 17
Number of Products by Stage and Target, H1 2018 19
Number of Products by Stage and Mechanism of Action, H1 2018 21
Number of Products by Stage and Route of Administration, H1 2018 24
Number of Products by Stage and Molecule Type, H1 2018 26
Aspergillosis - Pipeline by AlfaSigma SpA, H1 2018 27
Aspergillosis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2018 27
Aspergillosis - Pipeline by Astellas Pharma Inc, H1 2018 28
Aspergillosis - Pipeline by Basilea Pharmaceutica Ltd, H1 2018 28
Aspergillosis - Pipeline by Biosergen AS, H1 2018 28
Aspergillosis - Pipeline by Cerenis Therapeutics Holding SA, H1 2018 29
Aspergillosis - Pipeline by Cidara Therapeutics Inc, H1 2018 29
Aspergillosis - Pipeline by F2G Ltd, H1 2018 30
Aspergillosis - Pipeline by iCo Therapeutics Inc., H1 2018 30
Aspergillosis - Pipeline by Matinas BioPharma Holdings Inc, H1 2018 30
Aspergillosis - Pipeline by Merck & Co Inc, H1 2018 31
Aspergillosis - Pipeline by Nanomerics Ltd, H1 2018 31
Aspergillosis - Pipeline by Novabiotics Ltd, H1 2018 31
Aspergillosis - Pipeline by Pulmatrix Inc, H1 2018 32
Aspergillosis - Pipeline by Pulmocide Ltd, H1 2018 32
Aspergillosis - Pipeline by Scynexis Inc, H1 2018 33
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H1 2018 33
Aspergillosis - Pipeline by Viamet Pharmaceuticals Inc, H1 2018 33
Aspergillosis - Pipeline by Vical Inc, H1 2018 34
Aspergillosis - Pipeline by Visterra Inc, H1 2018 34
Aspergillosis - Dormant Projects, H1 2018 111
Aspergillosis - Dormant Projects, H1 2018 (Contd..1), H1 2018 112
Aspergillosis - Discontinued Products, H1 2018 113

List Of Figures

List of Figures
Number of Products under Development for Aspergillosis, H1 2018 11
Number of Products under Development by Companies, H1 2018 12
Number of Products under Development by Universities/Institutes, H1 2018 15
Number of Products by Targets, H1 2018 18
Number of Products by Stage and Targets, H1 2018 18
Number of Products by Mechanism of Actions, H1 2018 20
Number of Products by Stage and Mechanism of Actions, H1 2018 20
Number of Products by Top 10 Routes of Administration, H1 2018 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2018 23
Number of Products by Molecule Types, H1 2018 25
Number of Products by Stage and Molecule Types, H1 2018 25

Global Aspergillosis Drugs Industry Market Research Report

The Aspergillosis Drugs market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR of

USD 2960View Report

Aspergillosis - Pipeline Review, H1 2018

Aspergillosis - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Pipeline Review, H1 2018, provides an overview of the Aspergillosis (Infectious Disease) pipeline

USD 2000View Report

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2018

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2018Caspase 9 (Apoptotic

USD 3500View Report

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2018

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : May 2018
No. of Pages :128
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube